Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
|
|
- Sydney Boyd
- 5 years ago
- Views:
Transcription
1 Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
2 Objectives: By the end of this session, you will be able to: Identify the perioperative situations that are associated with better outcomes when glucose levels are optimal Recognize complications of diabetes that may result from the perioperative state Recall features of new classes of diabetes medications Evaluate a diabetes medication list in patients with chronic kidney disease
3 Why is this topic important? Diabetes is common and increasing in Canada and worldwide Individuals with diabetes are more likely to require surgery than those without diabetes Individuals with diabetes are at increased risk of postoperative surgical complications
4 Perioperative Goals Avoid hypoglycemia Prevent ketoacidosis Avoid marked hyperglycemia
5 Preoperative assessment Patient-related factors 1. Type 1 or Type 2; others 2. History of DKA/hyperosmolar states/hypoglycemia 3. Microvascular and macrovascular complications Procedure-related factors 1. Duration of surgery 2. Length of time NPO 3. Time of surgery
6 Does perioperative blood glucose control matter? Preoperative Intra Intraoperative Postoperative
7 Case You are seeing Deric Minors (DM), a 60 year old man with poorly controlled Type 2 diabetes mellitus who is scheduled for elective cholecystecomy in 2 weeks. He has a history of hypertension, longstanding diabetes and dyslipidemia. He does not have known microvascular or macrovascular complications. He has never had DKA or hypoglycemia. He takes metformin 1000 mg BID and sitagliptin 100 mg daily. His HbA1C is 12 % Should his surgery be delayed?
8 Does preoperative diabetes control matter? Acute hyperglycemia decreased immune function, increased surgical site infections in animal models Few trials of preoperative HbA1c, interventions Higher rate of complications in CABG with HbA1C above 7% compared with below 10.7 % surgical site infections versus 3.3 % (all patients) - Nicolini et al Int J Surg 2018 Conversation with patient and surgeon for consideration of delay for optimization
9 Which statement is true with regard to intraoperative glucose control? a) Maintenance of intraoperative blood glucose levels between 5-11 significantly lowers postoperative wound infections following total hip replacement b) Maintenance of intraoperative blood glucose levels between 5-11 significantly lowers postoperative wound infection following CABG c) Maintenance of intraoperative blood glucose levels between 5-11 significantly lowers postoperative for all procedures over 3 hours duration d) There is no high quality evidence that maintenance of intraoperative blood glucose levels between 5-11 significantly lowers postoperative wound infections
10 Boreland L, et al. Heart & Lung 2015; 44: CABG, coronary artery bypass grafting Diabetes Canada Guideline 2018; Chapter 16; Malcolm J, et al
11 2018 Diabetes Canada CPG Chapter 16. In-hospital Management of Diabetes Recommended glycemic targets for hospitalized people with diabetes Hospitalized population with diabetes Blood glucose targets (mmol/l) Non-critically ill preprandial: random: <10.0 Critically ill CABG intraoperatively Perioperatively for other surgeries Acute coronary syndrome Labour and delivery Less stringent targets may be appropriate in terminally ill patients or in people with severe comorbidities CABG, coronary artery bypass grafting NOT FOR COMMERCIAL USE
12 Does postoperative control of diabetes mellitus matter? RABBIT 2 trial (2011) Small single centre trial Showed better control of diabetes with basal-bolus insulin compared with SSI; 2/3 patients on oral regimen preop Lower rate of surgical site infections, other postoperative complications, higher risk of hypoglycemia
13 Blood glucose (mmol/l) 2018 Diabetes Canada CPG Chapter 16. In-hospital Management of Diabetes Basal-Bolus (BBI) Regimen Achieves Better Control than Sliding Scale (SSI) Alone RABBIT 2 RABBIT 2 Surgery * * * * SSI * ŧ ŧ SSI *p < 0.01; p < Admit Duration of treatment (days) BBI Randomi -zation *p < 0.001, ŧp = 0.02, p = Duration of treatment (days) BBI Adapted from: Umpierrez GE, et al. Diabetes Care 2007;30: Adapted from: Umpierrez GE, et al. Diabetes Care 2011;34:
14 Does postoperative control of diabetes mellitus matter? RABBIT 2 trial (2011) BUT: Nurse dedicated to rounding on patients re: glucose levels daily 24 hour access to endocrinologist Hypoglycemia in real world practice likely to be more significant Requires team-based approach with hypoglycemia protocols
15 Back to the case DM decided to delay his surgery as he was not having symptoms, and concentrate on improving his diabetes He lost weight, started on basal insulin (60 units HS), and added an SGLT2 inhibitor to his metformin and sitagliptin His HbA1c is now 6% and he is scheduled for surgery What would you recommend regarding his diabetes regimen preoperatively?
16 A 60 year old man with Type 2 diabetes mellitus scheduled for cholecystectomy is on empagliflozin 25 mg, sitagliptan 100 mg and long-acting insulin 60 units HS.. He has optimal control (HbA1C 6.0%). It was recommended that he hold his insulin the night before surgery. On arrival, for surgery, he says he feels unwell, with nausea but not vomiting. He denies chest pain, dyspnea, abdominal or fever. The nurse calls you. His vitals are BP 120/60, HR 90, RR24, POC glucose 9 mmol/l. He has not taken any medications other than those for his diabetes.
17 . Bloodwork shows the following: Na 136, K 4.5 Bicarbonate 10 Urea 8 Creat 85 ABGs: ph 7.22 HCO3=8 pco2 20 po2=95 RA Lactate normal What is the most likely cause of the bloodwork abnormalities?
18 What is the most likely cause of the bloodwork abnormalities? a) Hyperosmolar hyperglycemic state b) Diabetic ketoacidosis due to unrecognized Type 1 diabetes mellitus c) Euglycemic diabetic ketoacidosis due to SGLT2 inhibitor d) Sepsis
19 Demonstration of the cascade of clinical events and metabolic changes that contribute sequentially to progressive clinical deterioration and development of full-blown episodes of eudka. Julio Rosenstock, and Ele Ferrannini Dia Care 2015;38: by American Diabetes Association
20
21 Back to the case DM was on sitagliptin and metformin when his HbA1C was 12% He was started on an added SGLT2i was added without adequate control and then basal insulin (60 units HS) Were these appropriate, guideline-based choices?
22 HEALTHY BEHAVIOUR INTERVENTIONS 2018 Start healthy behaviour interventions (nutritional therapy, weight management, physical activity) +/- metformin A1C <1.5% above target AT DIAGNOSIS OF TYPE 2 DIABETES A1C 1.5% above target Symptomatic hyperglycemia and/or metabolic decompensation If not at glycemic target within 3 months, start/increase metformin Start metformin immediately Consider a second concurrent antihyperglycemic agent Initiate insulin +/- metformin If not at glycemic target If not at glycemic target Clinical CVD? YES NO Start antihyperglycemic agent with demonstrated CV benefit empagliflozin (Grade A, Level 1A) liraglutide (Grade A, Level 1A) canagliflozin* (Grade C, Level 2) If not at glycemic target * Avoid in people with prior lower extremity amputation See next page NOT FOR COMMERCIAL USE
23 Which one of the following is associated with the use of SGLT2 inhibitors? a) Weight gain b) Urogenital infections c) Hypertension d) Diarrhea
24 Patients with event (%) 2018 Diabetes Canada CPG Chapter 13. Pharmacologic Glycemic Management of Type 2 Diabetes Empagliflozin reduced CV events CV death, non-fatal MI, or non-fatal stroke PBO EMP A HR P NNT CV death, MI, stroke (%) CV deaths (%) < Nonfatal MI (%) Nonfatal stroke (%) Hosp. heart failure (%) All-cause mortality (%) < Placebo Empagliflozin 10 5 HR % CI (0.74, 0.99) P < for non-inferiority p=0.04 for superiority Months No. of patients Empagliflozin Placebo Zinman B et al. N Engl J Med 2015; DOI: /NEJMoa NOT FOR COMMERCIAL USE
25 2018 Diabetes Canada CPG Chapter 13. Pharmacologic Glycemic Management of Type 2 Diabetes Canagliflozin reduced CV events CV death, non-fatal MI, or non-fatal stroke Outcome (per 1000 pt-y) PBO CANA HR P or 95% CI NNT 5 CV death, MI, stroke CV deaths ( ) Nonfatal MI ( ) Nonfatal stroke ( ) Hosp. heart failure ( ) 63 All-cause mortality ( ) Placebo Canagliflozin HR % CI (0.75, 0.97) P < for non-inferiority p=0.02 for superiority No. of patients Canagliflozin Placebo Neal B et al. N Engl J Med 2017; DOI: /NEJMoa NOT FOR COMMERCIAL USE
26 Patients with event (%) 2018 Diabetes Canada CPG Chapter 13. Pharmacologic Glycemic Management of Type 2 Diabetes Liraglutide reduced CV events CV death, non-fatal MI, or non-fatal stroke PBO LIRA HR P NNT4 CV death, MI, stroke (%) CV death (%) Nonfatal MI (%) Nonfatal stroke (%) Hosp. heart failure (%) All-cause mortality (%) Placebo Liraglutide 5 HR % CI (0.78, 0.97) P < for non-inferiority p=0.01 for superiority Patients at risk Time from randomization (months) Liraglutide Placebo Marso SP et al. N Engl J Med 2016;375(4): NOT FOR COMMERCIAL USE
27 Add additional antihyperglycemic agent best suited to the individual by prioritizing patient characteristics (agents listed in alphabetical order by CV outcome data): Class Effect on CVD Outcomes Hypoglycemia Weight Relative A1C Lowering when added to metformin Other therapeutic considerations Cost GLP-1R agonists lira: Superiority in T2DM with clinical CVD exenatide LAR & lixi: Neutral Rare to GI side-effects, Gallstone disease Contraindicated with personal / family history of medullary thyroid cancer or MEN 2 Requires subcutaneous injection $$$$ SGLT2 inhibitors Cana & empa: Superiority in T2DM patients with clinical CVD Rare to Genital infections, UTI, hypotension, dose-related changes in LDL-C. Caution with renal dysfunction, loop diuretics, in the elderly. Dapagliflozin not to be used if bladder cancer. Rare diabetic ketoacidosis (may occur with no hyperglycemia). Increased risk of fractures and amputations with canagliflozin. Reduced progression of nephropathy & CHF hospitalizations with empagliflozin and canagliflozin in those with clinical CVD $$$ DPP-4 Inhibitors alo, saxa, sita: Neutral Rare Neutral Caution with saxagliptin in heart failure Rare joint pain $$$ Insulin glar: Neutral degludec: noninferior to glar Yes No dose ceiling, flexible regimens Requires subcutaneous injection $- $$$$ Thiazolidinediones Neutral Rare CHF, edema, fractures, rare bladder cancer (pioglitazone), cardiovascular controversy (rosiglitazone), 6-12 weeks for maximal effect $$ -glucosidase inhibitor (acarbose) Rare Neutral GI side-effects common Requires 3 times daily dosing $$ Insulin secretagogue: Meglitinide Sulfonylurea Yes Yes More rapid BG-lowering response Reduced postprandial glycemia with meglitinides but usually requires 3 to 4 times daily dosing. Gliclazide and glimepiride associated with less hypoglycemia than glyburide. Poor durability $$ $ Weight loss agent (orlistat) None GI side effects Requires 3 times daily dosing $$$
28 Add additional antihyperglycemic agent best suited to the individual by prioritizing patient characteristics (agents listed in alphabetical order by CV outcome data): Class Effect on CVD Outcomes Hypoglycemia Weight Relative A1C Lowering when added to metformin Other therapeutic considerations Cost GLP-1R agonists lira: Superiority in T2DM with clinical CVD exenatide LAR & lixi: Neutral Rare to GI side-effects, Gallstone disease Contraindicated with personal / family history of medullary thyroid cancer or MEN 2 Requires subcutaneous injection $$$$ SGLT2 inhibitors Cana & empa: Superiority in T2DM patients with clinical CVD Rare to Genital infections, UTI, hypotension, dose-related changes in LDL-C. Caution with renal dysfunction, loop diuretics, in the elderly. Dapagliflozin not to be used if bladder cancer. Rare diabetic ketoacidosis (may occur with no hyperglycemia). Increased risk of fractures and amputations with canagliflozin. Reduced progression of nephropathy & CHF hospitalizations with empagliflozin and canagliflozin in those with clinical CVD $$$ DPP-4 Inhibitors alo, saxa, sita: Neutral Rare Neutral Caution with saxagliptin in heart failure Rare joint pain $$$ Insulin glar: Neutral degludec: noninferior to glar Yes No dose ceiling, flexible regimens Requires subcutaneous injection $- $$$$ Thiazolidinediones Neutral Rare CHF, edema, fractures, rare bladder cancer (pioglitazone), cardiovascular controversy (rosiglitazone), 6-12 weeks for maximal effect $$ -glucosidase inhibitor (acarbose) Rare Neutral GI side-effects common Requires 3 times daily dosing $$ Insulin secretagogue: Meglitinide Sulfonylurea Yes Yes More rapid BG-lowering response Reduced postprandial glycemia with meglitinides but usually requires 3 to 4 times daily dosing. Gliclazide and glimepiride associated with less hypoglycemia than glyburide. Poor durability $$ $ Weight loss agent (orlistat) None GI side effects Requires 3 times daily dosing $$$
29 Add additional antihyperglycemic agent best suited to the individual by prioritizing patient characteristics (agents listed in alphabetical order by CV outcome data): Class Effect on CVD Outcomes Hypoglycemia Weight Relative A1C lowering when added to metformin Other therapeutic considerations Cost GLP-1R agonists lira: Superiority in T2DM with clinical CVD exenatide LAR & lixi: Neutral Rare to GI side-effects, Gallstone disease Contraindicated with personal / family history of medullary thyroid cancer or MEN 2 Requires subcutaneous injection $$$$ SGLT2 inhibitors Cana & empa: Superiority in T2DM patients with clinical CVD Rare to Genital infections, UTI, hypotension, dose-related changes in LDL-C. Caution with renal dysfunction, loop diuretics, in the elderly. Dapagliflozin not to be used if bladder cancer. Rare diabetic ketoacidosis (may occur with no hyperglycemia). Increased risk of fractures and amputations with canagliflozin. Reduced progression of nephropathy & CHF hospitalizations with empagliflozin and canagliflozin in those with clinical CVD $$$ DPP-4 Inhibitors alo, saxa, sita: Neutral Rare Neutral Caution with saxagliptin in heart failure Rare joint pain $$$ Insulin glar: Neutral degludec: noninferior to glar Yes No dose ceiling, flexible regimens Requires subcutaneous injection $- $$$$ Thiazolidinediones Neutral Rare CHF, edema, fractures, rare bladder cancer (pioglitazone), cardiovascular controversy (rosiglitazone), 6-12 weeks for maximal effect $$ -glucosidase inhibitor (acarbose) Rare Neutral GI side-effects common Requires 3 times daily dosing $$ Insulin secretagogue: Meglitinide Sulfonylurea Yes Yes More rapid BG-lowering response Reduced postprandial glycemia with meglitinides but usually requires 3 to 4 times daily dosing. Gliclazide and glimepiride associated with less hypoglycemia than glyburide. Poor durability $$ $ Weight loss agent (orlistat) None GI side effects Requires 3 times daily dosing $$$
30 A 63 year old man with chronic kidney disease (creatinine 190 umol/l, egfr 35) is having a total hip arthroplasty. His HbA1c is 10%. His current medications include metformin 500 mg BID, gliclazide extended release 60 mg daily, sitagliptan 100 mg OD and canagliflozin 100 mg OD. Which of the following of his current diabetes medications can be continued without dosage adjustment at his current creatinine clearance? a) Metformin, gliclazide b) Metformin, sitagliptan c) Sitagliptan, canaglifozin d) Gliclazide, canagliflozin
31 2018 Diabetes Canada CPG Chapter 13. Pharmacologic Glycemic Management of Type 2 Diabetes Antihyperglycemic Agents and Renal Function Alpha-glucosidase Inhibitors CKD Stage 5 4 3b 3a 1 or 2 egfr (ml/min/1.73 m 2 ): < Biguanides DPP-4 Inhibitors GLP-1 Receptor Agonists Insulin Secretagogues SGLT2 Inhibitors Thiazolidinediones Acarbose Canagliflozin* mg daily Dapagliflozin Empagliflozin Pioglitazone Use alternative agent Metformin mg daily Alogliptin 6.25 mg daily mg daily Linagliptin 15 Saxagliptin mg daily 50 Sitagliptin 25 mg daily 50 mg daily 50 Dulaglutide Exenatide Exenatide QW Liraglutide Lixisenatide Gliclazide Glimepiride Glyburide Repaglinide Rosiglitazone Insulins Dose adjustment required Fluid retention Caution 45 Do not initiate Dose adjustment not required * May be used for cardiorenal benefits in those with clinical CVD, A1C above target and egfr >30 ml/min/1.73m 2 60
32 Take home points Consider optimization of diabetes mellitus prior to elective surgery in patients with poor control; intraoperative in CABG 5-11 Preoperative and postoperative control likely matters; use more basal insulin and less reactive protocols such as QID SSI as long as hypoglycemia can be avoided New medications (some) SGLT2i and GLP-1 agonists reduce cardiovascular outcomes, renal outcomes Most diabetes medications require dose reductions with CKD use the Diabetes Canada graphic (Appendix )
DIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and diagnosis of type 2 diabetes in adults Assess risk factors for
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationMANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC
MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC Faculty Disclosure Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Endocrinologist,
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationFaculty/Presenter Disclosure
DIABETES UPATE 2016 Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria: eli lilly sanofi;
More informationCASES DR TINA KADER MCGILL JGH; LMC CVPH CDE
CASES DR TINA KADER MCGILL JGH; LMC CVPH CDE Faculty/Presenter Disclosure Faculty/Presenter: tina kader Relationships with commercial interests: Grants/research support: BI; Sanofi Speaker s bureau/honoraria:
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationContent Development Committee
1 Content Development Committee Cardiologists: Family Physicians: Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA, FCCS (Chair) Associate Head, Division of Cardiology, St. Michael s Hospital Professor,
More informationCanadian Diabetes Association 2013 Clinical Practice Guidelines
Canadian Diabetes Association 2013 Clinical Practice Guidelines The Essentials (Updated d November 2016) 2016 1 Faculty/Presenter Disclosure Faculty: Alan Bell MD CCFP Relationships with commercial and
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More information8/12/2016. Diabetes Management Across the Spectrum of Kidney Function. Andrew Bzowyckyj. Learning Objectives. Ashley Crowl
Diabetes Management Across the Spectrum of Kidney Function Andrew Bzowyckyj PharmD, BCPS, CDE Clinical Assistant Professor School of Pharmacy University of Missouri-Kansas City Kansas City, MO Ashley Crowl
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationRational Goal-Setting and Management of Diabetes in the Elderly
Rational Goal-Setting and Management of Diabetes in the Elderly Michael Shannon, MD Medical Director, Physicians of Southwest Washington Clinical Assistant Professor, University of Washington Outline of
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationUpdate on Diabetes Canadian Society of Internal Medicine Oct 11, 2018
https://www.australiawidefirstaid.com.au/what-is-diabetes/ Update on Diabetes Canadian Society of Internal Medicine Oct 11, 2018 Praveena Sivapalan MD, FRCPC Division of General Internal Medicine, University
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More information